Systemic muscular weakness after botulinum toxin A administration: a review of the literature

ConclusionBased on data from the identified cases of systemic muscle weakness with botulinum toxin A, this adverse event was more common in female, younger, patients with spasticity or neurogenic detrusor overactivity indication or those receiving abobotulinum toxin A formulation and/or higher botulinum toxin A doses. A prevention strategy may include reducing the dose of botulinum toxin A to those recommended by the US FDA.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research